Cytokinetics Waited 27 Years for Its First Drug. Now It Wants to Double Down.

Setting dual primary endpoints is the biotech equivalent of calling your shot from half court. You have to hit both. Miss either one, and the trial fails.

Topline results came out on May 5, 2026: aficamten hit both endpoints with statistical significance. Quality of life improved. Exercise capacity improved. And the secondary endpoints fell in line too: more patients saw meaningful improvements in their heart failure symptoms (measured by NYHA class), exercise efficiency got better, and NT-proBNP, a biomarker that signals cardiac stress, dropped significantly.

The Rival That Already Fumbled

This is where the story gets really interesting. Cytokinetics isn't the only company with a cardiac myosin inhibitor (the class of drugs that work by dialing down the heart's excessive squeezing). Bristol Myers Squibb sells Camzyos (mavacamten), which was the first drug in this class to hit the market for obstructive HCM.

Camzyos is doing well commercially, and BMS has been riding it as a growth engine. The company also tried to extend Camzyos into non-obstructive HCM, the same territory Cytokinetics just conquered.

They failed. BMS's Phase 3 trial in non-obstructive HCM fell short, and there's no clear path to retry anytime soon.

So picture this: Cytokinetics, the scrappy underdog that spent 27 years without an approved product, just succeeded in a space where the pharmaceutical giant across the street already face-planted. In non-obstructive HCM, aficamten is now essentially running unopposed. No approved cardiac myosin inhibitor exists for this indication, and the only serious competitor just got knocked out of the race.

What Wall Street Thinks

Analysts noticed. After the ACACIA-HCM readout, firms including Citi, Barclays, Mizuho, UBS, RBC, and JPMorgan either raised their price targets or flagged the data as a key catalyst. Some used the word "groundbreaking." The consensus view: the trial was a genuine de-risking event that significantly boosts the odds of a label expansion into non-obstructive HCM.

Not everyone is popping champagne, though. UBS and Bank of America reportedly maintained Neutral ratings, pointing out that a positive trial doesn't guarantee regulatory approval, and that real prescription volume won't show up in the numbers until later in 2026. Fair enough. The remaining hurdles are regulatory review, labeling specifics, and the always-unpredictable grind of commercial launch execution.

But the skeptics have a tougher case to make now. The drug hit both primary endpoints. The safety profile looked manageable (hypertension was the main adverse event in the obstructive HCM trial, and the label requires monitoring for drops in heart pumping function). And the competitive landscape essentially cleared itself.

The Math That Matters

Let's zoom out. Myqorzo launched in the U.S. in late January 2026 for obstructive HCM. That market alone is significant. But if Cytokinetics can secure an expanded label covering non-obstructive HCM, the addressable patient population doesn't just grow; it potentially more than doubles, based on the prevalence numbers.

The company also secured EU-wide marketing authorisation for Myqorzo (aficamten) from the European Commission in February 2026, adding another major geography to the revenue map. A regional deal with Sanofi covers China and surrounding markets. The global commercial story is taking shape rapidly for a company that, not long ago, had nothing to sell.

For a biotech that accumulated $3.49 billion in losses before ever selling a single pill, the transformation is remarkable. Cytokinetics went from a research-stage company that most investors had given up on to one sitting at the center of the cardiac myosin inhibitor class, with a first-mover advantage in a space its bigger rival already lost.

What Comes Next

The ACACIA-HCM data will need to translate into an FDA submission and, eventually, a label expansion. The trial also has a second part running out to 72 weeks, which will provide longer-term safety and efficacy data (full study completion is expected by late 2026). If that data holds up, the regulatory path should be relatively straightforward, given the strength of the primary results.

Meanwhile, BMS isn't standing still. They have a next-generation cardiac myosin inhibitor called MYK-224 in Phase 2 for HFpEF, and they're pursuing a pediatric expansion for Camzyos with an FDA decision expected in late 2026. The class competition isn't over; it's just shifting to new battlefields.

But right now, in the non-obstructive HCM space, Cytokinetics has the field to itself. After 27 years of patience, that's a pretty good place to be.

One Shot to Silence a Gene Forever

Intellia just delivered the first successful Phase 3 trial for an in vivo CRISPR therapy, cutting hereditary angioedema attacks by 87% with a single infusion. The results could reshape how we think about treating genetic diseases forever.